Alto Neuroscience (ANRO) Shares Outstanding (2023 - 2026)
Alto Neuroscience (ANRO) posted Shares Outstanding (Entity) of $35.1 million for Q1 2026, up 9.8% sequentially from $31.9 million in Q4 2025, and up 29.48% YoY from $27.1 million in Q1 2025.
Alto Neuroscience (ANRO) Shares Outstanding (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Shares Outstanding (Entity) for 4 years, with the latest figure at $35.1 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 29.48% year-over-year to $35.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.1 million (up 29.48% YoY) and the FY2025 annual result came in at $31.9 million, up 18.29% from the prior year.
- Shares Outstanding (Entity) grew to $35.1 million in Q1 2026 per ANRO's latest filing, from $31.9 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $35.1 million in Q1 2026 and troughed at $3.8 million in Q1 2023.
- A 4-year average of $20.2 million and a median of $27.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) soared 614.12% in 2024, then advanced 0.45% in 2025.
- Over 4 years, Shares Outstanding (Entity) stood at $3.8 million in 2023, then soared by 604.23% to $27.0 million in 2024, then gained by 18.29% to $31.9 million in 2025, then climbed by 9.8% to $35.1 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $35.1 million, $31.9 million, and $27.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 42.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.89 Mn |
| Mar 31, 2026 | 32.89 Mn |
| Dec 31, 2025 | 28.85 Mn |
| Sep 30, 2025 | 27.10 Mn |
| Jun 30, 2025 | 27.07 Mn |
| Mar 31, 2025 | 27.05 Mn |
| Dec 31, 2024 | 24.60 Mn |
| Sep 30, 2024 | 26.96 Mn |
| Jun 30, 2024 | 26.91 Mn |
| Mar 31, 2024 | 17.60 Mn |
| Dec 31, 2023 | 3.73 Mn |
| Sep 30, 2023 | 3.74 Mn |
| Jun 30, 2023 | 3.72 Mn |
| Mar 31, 2023 | 3.69 Mn |